FBIO logo

FBIOFortress Biotech Inc

$2.66
$0.09
(3.50%)
Today
Updated: 03:04 PM EDT
Reported EarningsMay 14
Mkt Cap$85.37M
Vol438,600.00
News
all
press releases
Fortress Biotech (NASDAQ:FBIO) Issues Quarterly Earnings Results, Misses Estimates By $0.32 EPS
Fortress Biotech (NASDAQ:FBIO - Get Free Report) posted its quarterly earnings data on Tuesday. The biopharmaceutical company reported ($0.21) earnings per share (EPS) for the quarter, missing the...
MarketBeat
News Placeholder
More News
News Placeholder
Fortress Biotech (NASDAQ:FBIO) Lowered to Hold Rating by Wall Street Zen
Wall Street Zen cut shares of Fortress Biotech from a "buy" rating to a "hold" rating in a report on Saturday...
MarketBeat
News Placeholder
Fortress Biotech (FBIO) Projected to Post Quarterly Earnings on Monday
Fortress Biotech (NASDAQ:FBIO) will be releasing its Q4 2025 earnings before the market opens on Monday, March 30. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2026-3-30-fortress-biotech-inc-stock...
MarketBeat
News Placeholder
Fortress Biotech (NASDAQ:FBIO) Cut to "Hold" at Zacks Research
Zacks Research downgraded Fortress Biotech from a "strong-buy" rating to a "hold" rating in a research note on Monday...
MarketBeat
News Placeholder
Fortress Biotech (NASDAQ:FBIO) Shares Pass Above Two Hundred Day Moving Average - What's Next?
Fortress Biotech (NASDAQ:FBIO) Share Price Crosses Above Two Hundred Day Moving Average - What's Next...
MarketBeat
News Placeholder
Fortress Biotech (NASDAQ:FBIO) Stock Passes Above Two Hundred Day Moving Average - Here's Why
Fortress Biotech (NASDAQ:FBIO) Stock Passes Above 200 Day Moving Average - Should You Sell...
MarketBeat
News Placeholder
FBIO Shares Rally After Unit Sells Priority Review Voucher For $205 Million: Retail Now Pins Hopes On Gene Therapy
Fortress said that its majority-owned unit Cyprium Therapeutics has entered into a definitive asset purchase agreement to sell its Rare Pediatric Disease Priority Review Voucher to Sentynl Therapeutics.
Stocktwits
News Placeholder
Fortress Biotech's (FBIO) Buy Rating Reiterated at HC Wainwright
HC Wainwright reiterated a "buy" rating and issued a $17.00 price objective on shares of Fortress Biotech in a research report on Monday...
MarketBeat
News Placeholder
Fortress Biotech (NASDAQ:FBIO) Shares Cross Above 200-Day Moving Average - Here's What Happened
Fortress Biotech (NASDAQ:FBIO) Stock Price Crosses Above 200-Day Moving Average - Time to Sell...
MarketBeat
News Placeholder
Fortress Biotech (NASDAQ:FBIO) Shares Cross Above 200-Day Moving Average - What's Next?
Fortress Biotech (NASDAQ:FBIO) Share Price Passes Above 200-Day Moving Average - Here's Why...
MarketBeat
<
1
2
...
>